Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAPP vs GPP in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07540390Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- Dec 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start May 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07540390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540390.